ATLANTA, April 24 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is conducting the 2008 Cardiac Allograft Symposium at its corporate headquarters training facility in suburban Atlanta, GA, April 25-26. The program will focus on current clinical outcomes, indications and surgical techniques of aortic valve replacement utilizing aortic allografts and the CryoValve(R) SG pulmonary human heart valves.
"As leaders in human tissue transplantation and cardiac reconstruction, it is both an honor and a privilege to host this advanced surgical training at our state-of-the-art facility and laboratory," said Steven G. Anderson, president and chief executive officer of CryoLife, Inc. "We look forward to bringing together this eminent group of cardiovascular surgeons and offering them the opportunity to learn the newest surgical techniques utilizing human aortic valves and our recently FDA-cleared CryoValve SG pulmonary valve."
The symposium's distinguished faculty includes: John W. Brown, M.D., professor of cardiothoracic surgery, Indiana University School of Medicine, Indianapolis, Ind; Paul E. Stelzer, M.D., senior faculty, cardiothoracic surgery, Mount Sinai School of Medicine, New York, N.Y.; Craig R. Saunders, M.D., chairman of cardiothoracic surgery, Saint Barnabas Health Care System, Newark, N.J.; Kent E. Ward, M.D., associate professor of pediatric cardiology, University of Oklahoma Health Sciences Center, Oklahoma City, Okla; Kenton J. Zehr, M.D., professor of surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.; and Edward Nowicki, M.D., assistant head, clinical investigations, Heart & Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
The program director is William F. Northrup, III, M.D., vice president, medical relations and education at CryoLife. Steven Goldstein, Ph.D., senior director, tissue technologies at CryoLife is also on the faculty. Some 20 surgeons from around the United States are expected to participate in the symposium.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. Beginning May 1, 2008 CryoLife will distribute Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.
For additional information about the company, visit CryoLife's Web site: www.cryolife.com.
SOURCE CryoLife, Inc.
